Brian Goff - 09 Jun 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Reporting relationship: Director
Issuer ticker: NTLA
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2026, 19:02:49 UTC
Prior SEC filing: 06 Apr 2026
Next SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: James Basta, attorney-in-fact

Key filing fact

Brian Goff filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 10 Jun 2026.

Key facts

This page summarizes Brian Goff's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2026, 19:02.

Change

Previous filing in this sequence was filed on 06 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001546216 Primary reporting owner

Goff Brian

Relationship: Director
Address: C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE
Signature: James Basta, attorney-in-fact
Signature date: 10 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NTLA transaction

Common Stock

Award

Transaction value
Shares: +9,200
Change %: +39%
Price: $0.000000^*
Shares after: 32,609
Date: 09 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NTLA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +13,300
Change %
Price: $0.000000^*
Shares after: 13,300
Date: 09 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,300
Exercise price: $12.89
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Footnote F2

This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.